User profiles for Alex B. Blair
 | Alex BlairMemorial Sloan Kettering Cancer Center Verified email at mskcc.org Cited by 2766 |
Survival in locally advanced pancreatic cancer after neoadjuvant therapy and surgical resection
Objective: The aim of the study was to identify the survival of patients with locally advanced
pancreatic cancer (LAPC) and assess the effect of surgical resection after neoadjuvant …
pancreatic cancer (LAPC) and assess the effect of surgical resection after neoadjuvant …
Defining and predicting early recurrence in 957 patients with resected pancreatic ductal adenocarcinoma
Objectives: To establish an evidence-based cut-off to differentiate between early and late
recurrence and to compare clinicopathologic risk factors between the two groups. Summary …
recurrence and to compare clinicopathologic risk factors between the two groups. Summary …
[PDF][PDF] Multi-omic analyses of changes in the tumor microenvironment of pancreatic adenocarcinoma following neoadjuvant treatment with anti-PD-1 therapy
Successful pancreatic ductal adenocarcinoma (PDAC) immunotherapy necessitates
optimization and maintenance of activated effector T cells (Teff). We prospectively collected and …
optimization and maintenance of activated effector T cells (Teff). We prospectively collected and …
Is a pathological complete response following neoadjuvant chemoradiation associated with prolonged survival in patients with pancreatic cancer?
Objectives: To describe the survival outcome of patients with borderline resectable or locally
advanced pancreatic ductal adenocarcinoma (BR/LA-PDAC) who have a pathologic …
advanced pancreatic ductal adenocarcinoma (BR/LA-PDAC) who have a pathologic …
Implications of the pattern of disease recurrence on survival following pancreatectomy for pancreatic ductal adenocarcinoma
Background After radical resection of pancreatic ductal adenocarcinoma (PDAC), approximately
80% of patients will develop disease recurrence. It remains unclear to what extent the …
80% of patients will develop disease recurrence. It remains unclear to what extent the …
BRCA1/BRCA2 germline mutation carriers and sporadic pancreatic ductal adenocarcinoma
… Author links open overlay panel Alex B. Blair MD a , Vincent P. Groot MD a , Georgios …
Weiss MD, FACS a b , Michael Goggins MD b c d , Christopher L. Wolfgang MD, PhD, FACS …
Weiss MD, FACS a b , Michael Goggins MD b c d , Christopher L. Wolfgang MD, PhD, FACS …
Dissecting the stromal signaling and regulation of myeloid cells and memory effector T cells in pancreatic cancer
AB Blair, VM Kim, ST Muth, MT Saung, N Lokker… - Clinical Cancer …, 2019 - AACR
Purpose: Myeloid cells are a prominent immunosuppressive component within the stroma of
pancreatic ductal adenocarcinoma (PDAC). Previously, targeting myeloid cells has had …
pancreatic ductal adenocarcinoma (PDAC). Previously, targeting myeloid cells has had …
Recurrence after neoadjuvant therapy and resection of borderline resectable and locally advanced pancreatic cancer
Introduction The incidence, timing, and implications of recurrence in patients who underwent
neoadjuvant treatment and surgical resection of borderline resectable (BRPC) or locally …
neoadjuvant treatment and surgical resection of borderline resectable (BRPC) or locally …
Outcome of patients with borderline resectable pancreatic cancer in the contemporary era of neoadjuvant chemotherapy
Introduction Approximately, 20% of patients with pancreatic ductal adenocarcinoma have
resectable disease at diagnosis. Given improvements in locoregional and systemic therapies, …
resectable disease at diagnosis. Given improvements in locoregional and systemic therapies, …
A roadmap for aspiring surgeon-scientists in today's healthcare environment
Objective: Surgeon-scientists are an essential component of the field of academic surgery,
contributing to the fundamental understanding of disease and the discovery of innovative …
contributing to the fundamental understanding of disease and the discovery of innovative …